Reporting for WBUR, Carey Goldberg highlights how MIT researchers have developed a new RNA editing tool that could be used to tweak a gene that raises the risk of Alzheimer’s disease. As the effects of RNA editing are not permanent, “it's almost like a small, pill-like version of gene therapy,” explains research scientist and McGovern Fellow Omar Abudayyeh.
STAT reporter Sharon Begley writes that Prof. Feng Zhang and his colleagues have turned “a jumping gene — aka a transposon, or mobile genetic element — into a mini TaskRabbit gig worker: With an assist from CRISPR enzymes, it zips over to the part of the genome whose address it is given and delivers a package of DNA, pronto.”
President Emerita Susan Hockfield discusses her new book, “The Age of Living Machines,” her work as a neuroscientist, and the future of science and technology during a curated lunch conversation with HUBweek and Boston.com. Hockfield explains that a revolution spurred by the convergence of biology with engineering will lead to new technologies built by biology.
In an excerpt from her new book published in The Wall Street Journal, President Emerita Susan Hockfield explores how the convergence between biology and engineering is driving the development of new tools to tackle pressing human problems. Hockfield writes that for these world-changing technologies to be realized requires “not only funding and institutional support but, more fundamentally, a commitment to collaboration among unlikely partners.”
President Emerita Susan Hockfield speaks with Jim Braude of WGBH’s Greater Boston about her book, “The Age of Living Machines.” “We are looking at a population of over 9.7 billion by 2050,” explains Hockfield. “We are not going to get there without war or epidemics or starvation if we don’t develop technologies that will allow us to provide energy, food, water, health and health care sustainably.”
Boston Globe reporters Ysabelle Kempe and Felice Freyer write that MIT is launching a new Down syndrome research center with a gift from the Alana Foundation. “I really want people with different conditions and different ability to feel they are not different, to feel that they belong, and to enhance their capability to interact and to enjoy life,” explains Prof. Li-Huei Tsai.
MIT is launching a new Down syndrome research center thanks to a gift from the Alana Foundation, reports the AP. The center “will combine the expertise of scientists and engineers in an effort to increase understanding of the biology and neuroscience of Down syndrome.”
New York Times reporter Heather Murphy highlights a new study co-authored by Prof. Peter Reddien that details the master gene responsible for enabling worms to regenerate. “Something has to decide in cells which notes to play; which genes to turn on,” explains Reddien. “There are some genes whose function it is to tell other genes whether to be on or off. This is one of those kinds of genes.”
TIME reporter Alice Park writes that in a Nature commentary, an international group of scientists has called for a temporary ban on studies using gene-editing on human embryos. “Our question is, how should nations make decisions about technologies like gene editing going forward?” says Prof. Eric Lander, director of the Broad Institute and one of the authors of the commentary.
Associated Press reporter Malcom Ritter writes that an international team of scientists – including a number of MIT researchers – has called for a moratorium on making babies with genetically engineered DNA. “The moratorium would allow time for discussion of technical, scientific, societal and ethical issues that must be considered,” explains Ritter.
Prof. Aviv Regev speaks with the Associated Press about the Human Cell Atlas Consortium, which is aimed at cataloging all the cells in the human body in an effort to better understand human diseases. "This is not going to cure all disease immediately," she says, but "it is a critical stepping stone."
MIT researchers developed a new technique to make a more effective and precise CRISPR gene editing system, reports Eileen Drage O’Reilly for Axios. The system uses the new enzyme Cas12b, which has a “small size and precise targeting [that] will enable it to be used for in vivo applications in primary human cells,” O’Reilly explains.
Guardian reporter Ian Sample writes that MIT startup Synlogic are developing a “living” medicine” made from genetically modified bugs. “By engineering these bacteria, we are able to control how they operate in the human gastrointestinal tract,” says Caroline Kurtz of Synlogic. “It allows us to think about many other diseases where you may need to produce something beneficial, or remove something that is toxic for the patient.”
Forbes reporter Fiona McMillan writes that MIT researchers have engineered an anti-bacterial peptide found in wasp venom in an effort to create a new antibiotic. McMillan writes that the researchers, “gained new insight into which structural attributes work best, either alone or in combination. In this way, they were able to tweak the peptide’s structure to obtain optimal function.”
MIT researchers have repurposed the toxic venom found in wasps to create a new drug that could potentially be used to kill bacteria, reports the Xinhua news agency. “The venom-derived peptide is believed to kill microbes by disrupting bacterial cell membranes,” Xinhua explains.